Investor News

Interim Report for the second quarter

For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.
Read More

Lunds Universitet och PHI samarbetar kring utveckling av nya 3D-cellodlingsmetoder för immunterapiforskning

Baserat på PHI:s befintliga HoloMonitor-teknik, har institutionen för Immun­teknologi vid Lunds Universitet och Phase Holographic Imaging (PHI) avtalat om att gemensamt utveckla nya metoder för 3‑dimensionell cell­odling. Detta för att möta ett akut och snabbt växande behov av dessa metoder inom cancerforskningen.
Read More

Lund University and PHI partner to develop novel 3D cell culturing methods for immunotherapy research

Based on PHI’s current HoloMonitor technology, the Department of Immunotechnology at Lund University and Phase Holographic Imaging (PHI) recently agreed to jointly develop novel 3-dimensional cell culturing methods to meet the urgent need for such methods.
Read More

Rights issue enables market expansion

The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.
Read More

Kallelse till årsstämma i Phase Holographic Imaging PHI (publ)

Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.
Read More
BRAF Mutation

New CEO commentary: “Understanding Skin Cancer”

PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.
Read More

Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer

Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.
Read More

PHI´s new software available for customer delivery

In this first version of App Suite three common analyzes are included: cell proliferation, cell motility, and cell quality control. App Suite will be rapidly expanded with additional applications. HoloMonitor® App Suite 2.0 is scheduled to be released to customers in Q4 2018.
Read More

Kommuniké från extra bolagsstämma i Phase Holographic Imaging PHI AB (publ)

Igår, den 18 juni 2018, hölls extra bolagsstämma i Phase Holographic Imaging PHI AB (publ). Stämman röstande enhälligt för föreslagna beslut gällande nyemission.
Read More

PHI and BioSpherix sign co-marketing agreement

Phase Holographic Imaging (PHI) and BioSpherix recently signed a collaboration agreement aiming to co-market the companies’ complementary product lines. BioSpherix, NY USA, manufactures and markets advanced cell incubators.
Read More